Vasa Therapeutics is developing therapeutics that target the pathophysiology of cardiovascular aging, focusing on conditions such as heart failure, peripheral artery disease, and sarcopenia. Their preclinical programs include a personalized medicine treatment for heart failure with preserved ejection fraction and long-acting peptide analogs aimed at mitigating muscle loss and cardiovascular risks in aging populations.
Funding
Funding not disclosed
Founders
Product
Problem
Cardiovascular diseases, including heart failure, peripheral artery disease (PAD), and sarcopenia, present a growing global health challenge, particularly in aging populations. Current treatments often fail to address the underlying pathophysiology of these age-related conditions, leading to high mortality rates and substantial healthcare costs. There is a significant unmet need for innovative therapies that can effectively target the mechanisms driving cardiovascular aging and improve patient outcomes.
Solution
Vasa Therapeutics is developing targeted therapeutics to address the pathophysiology of cardiovascular aging and related diseases. Their approach includes a personalized medicine treatment (VS-041) for heart failure with preserved ejection fraction (HFpEF), designed to reduce cardiac fibrosis by inhibiting the release of signaling collagen fragments. They are also developing long-acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease, with potential applications in muscle atrophy, heart failure, chronic kidney disease, and PAD. Additionally, Vasa is working on a best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
Target Audience
The primary target audience includes patients suffering from heart failure, peripheral artery disease, sarcopenia, and related cardiovascular conditions, as well as clinicians specializing in cardiology and geriatric medicine.
Features
- VS-041: Personalized medicine approach targeting cardiac fibrosis in HFpEF patients.
- Long-acting apelin peptide analogs: Potential for combination therapy in obesity patients at risk for muscle loss and cardiovascular disease.
- CamKIId inhibitor: Designed for heart failure and life-threatening arrhythmias.
- Computational chemistry and design platform: Used for strategic identification of biological targets and design of small molecule or peptide therapeutics.